Department of Anaesthesiology and Intensive Care, Neurology, University of Debrecen, Health and Medical Science Centre, Debrecen, Hungary.
J Crit Care. 2012 Aug;27(4):337-43. doi: 10.1016/j.jcrc.2011.11.002. Epub 2012 Jan 9.
The pathophysiology of sepsis-associated encephalopathy (SAE) is not entirely clear, but one of the possible underlying mechanisms is the alteration of the cerebral microvascular function. The aim of the present work was to test whether cerebral vasomotor reactivity is impaired in patients with severe sepsis.
Patients fulfilling the criteria of clinical sepsis and showing at least 2 organ dysfunctions were included (n = 16). Nonseptic healthy persons without previous diseases affecting cerebral vasoreactivity served as controls (n = 16). Transcranial Doppler blood flow velocities were measured at rest and at 5, 10, 15, and 20 minutes after intravenous administration of 15 mg/kg acetazolamide. The time course of the acetazolamide effect on cerebral blood flow velocity (cerebrovascular reactivity [CVR]) and the maximal vasodilatory effect of acetazolemide (cerebrovascular reserve capacity [CRC]) were compared among the groups.
Absolute blood flow velocities after administration of the vasodilator drug did not differ between control and septic patients. Assessment of the time course of the vasomotor reaction showed that patients with sepsis reacted in a similar fashion to the vasodilatory stimulus than control persons. When assessing the maximal vasodilatory ability of the cerebral arterioles to acetazolamide during vasomotor testing, we found that there was no difference in vasodilatory ability between septic and healthy subjects (CRC controls, 54.8% ± 11.1%; CRC sepsis-associated encephalopathy, 61.1% ± 34.4%; P = .49).
We conclude that cerebrovascular reactivity is not impaired in patients with severe sepsis. It is conceivable that cerebral vasoreactivity may be differently involved at different severity stages of the septic process.
脓毒症相关性脑病(SAE)的病理生理学尚不完全清楚,但其中一个可能的潜在机制是大脑微血管功能的改变。本研究旨在检测严重脓毒症患者的脑血管反应性是否受损。
纳入符合临床脓毒症标准且至少有 2 个器官功能障碍的患者(n = 16)。选择无影响脑血管反应性的既往疾病的非脓毒症健康人作为对照组(n = 16)。静脉注射 15mg/kg 乙酰唑胺后,在静息状态和 5、10、15 和 20 分钟时测量经颅多普勒血流速度。比较各组乙酰唑胺对脑血流速度(脑血管反应性 [CVR])的作用时间过程和乙酰唑胺的最大血管扩张作用(脑血管储备能力 [CRC])。
血管扩张剂药物给药后绝对血流速度在对照组和脓毒症患者之间无差异。评估血管运动反应的时间过程表明,脓毒症患者对血管扩张刺激的反应与对照组相似。在血管运动试验中评估大脑小动脉对乙酰唑胺的最大血管扩张能力时,我们发现脓毒症和健康受试者之间的血管扩张能力没有差异(CRC 对照组,54.8% ± 11.1%;CRC 脓毒症相关性脑病,61.1% ± 34.4%;P =.49)。
我们的结论是,严重脓毒症患者的脑血管反应性未受损。可以想象,在脓毒症过程的不同严重程度阶段,脑血管反应性可能会有不同的参与。